Hugo Lemessurier

Director at Spero Therapeutics

Hugo LeMessurier has over 15 years of experience in various roles in business consulting and advisory services. Hugo is the Managing Director of LeMessurier Solutions, a boutique consultancy specializing in strategic business planning, investor readiness, and government incentives. Hugo has also served as a Case Manager for Commercialisation Australia and COMET business Advisor.

In addition, Hugo has held directorship positions in several companies within the biotechnology and medical industries, including Himuka AM Australia Pty Ltd, Abcuro, Inc, Spero Therapeutics, Calpain Therapeutics Pty Ltd, Silentium Defence, Coolsan Australia Pty Ltd, and Genics. These roles have allowed him to provide strategic advice and guidance in various areas of expertise, such as drug development, continuous sanitation solutions, and risk mitigation in food production systems.

Furthermore, Hugo has been involved in corporate development for Change Climate and served as a strategic advisor for Embarr Pty Ltd, a company that develops fire protection systems, and for Silentium Defence, a company specializing in defense technology.

Overall, Hugo LeMessurier's work experience showcases their expertise in business strategy, corporate advisory, and industry-specific consulting for clients in the biotechnology, medical, and food industries.

Hugo LeMessurier's education history begins in 1989 when they enrolled in the University of Adelaide. Hugo pursued a Bachelor of Science degree, focusing on Microbiology, Genetics, and Immunology. Hugo completed their degree in 1993.

Afterward, in 1992, Hugo attended the University of South Australia for a year. There, they studied Business, with a specific emphasis on Marketing and Information Systems.

More recently, in 2018, Hugo furthered their education by attending Strategyzer. Although they did not pursue a specific degree, they engaged in the study of Business Models during their time at this institution.

Links

Timeline

  • Director

    October, 2016 - present

View in org chart